The Prognostic Value of the EASIX Score in Patients with Metastatic Pancreatic Cancer
Diagnostics · 09.07.2025 · 15 (14) · 1740
DOI: 10.3390/diagnostics15141740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 09.07.2025. Verfasst von Vahit Can Cavdar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul 34098, Turkey. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Pancreatic cancer (PC) is an aggressive malignancy with a poor prognosis, frequently diagnosed at a metastatic stage. The identification of accessible, cost-effective prognostic biomarkers is critical for optimizing treatment strategies. The Endothelial Activation and Stress Index (EASIX), calculated using lactate dehydrogenase (LDH), creatinine, and platelet count, reflects endothelial dysfunction and has shown prognostic value in hematological cancers. However, its utility in metastatic PC remains unexplored. This study is the first to evaluate the prognostic significance of the EASIX in patients with metastatic PC receiving first-line FOLFIRINOX chemotherapy.
Methods
This retrospective cohort study analyzed 204 patients diagnosed with metastatic pancreatic adenocarcinoma at Istanbul Training and Research Hospital between 2020 and 2025. All patients received FOLFIRINOX as first-line therapy. EASIX was calculated as LDH (U/L) × creatinine (mg/dL)/platelet count (109/L). A cut-off value of 1.33 was used to stratify patients into low and high EASIX groups. Overall survival (OS) was assessed using Kaplan–Meier analysis and compared with the log-rank test.
Results
The mean patient age was 63.0 ± 9.4 years; 61.8% were male. There were no significant differences in baseline characteristics between groups. Patients with EASIX ≥ 1.33 had significantly lower platelet counts and higher LDH and creatinine levels. Median OS was 14 months for EASIX < 1.33 and 8 months for EASIX ≥ 1.33 (p < 0.001).
Conclusions
EASIX is a simple, inexpensive prognostic marker associated with overall survival in metastatic PC. Its integration into clinical practice may facilitate early risk stratification. Further prospective studies are needed to confirm its prognostic utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul 34098, Turkey.
- Department of Internal Medicine, Beylikduzu State Hospital, Istanbul 34500, Turkey.
- Department of Medical Oncology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul 34093, Turkey.
ORCID-Profile: Vahit Can Cavdar, Yalcin Gokmen, Ilkay Gulturk, Cigdem Usul Afsar
Zitieren
APA
Cavdar, V. C., Gokmen, Y., Aric, M., Altunkaya, T., Erdem, C. G., Gulturk, I., & Afsar, C. U. (2025). The Prognostic Value of the EASIX Score in Patients with Metastatic Pancreatic Cancer. Diagnostics, 15(14), 1740. https://doi.org/10.3390/diagnostics15141740
Vancouver
Cavdar VC, Gokmen Y, Aric M, Altunkaya T, Erdem CG, Gulturk I, et al. The Prognostic Value of the EASIX Score in Patients with Metastatic Pancreatic Cancer. Diagnostics. 2025;15(14):1740. doi:10.3390/diagnostics15141740
BibTeX
@article{Cavdar2025,
author = {Cavdar, Vahit Can and Gokmen, Yalcin and Aric, Mert and Altunkaya, Tugba and Erdem, Cennet Gizem and Gulturk, Ilkay and Afsar, Cigdem Usul},
title = {The Prognostic Value of the EASIX Score in Patients with Metastatic Pancreatic Cancer},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {14},
pages = {1740},
doi = {10.3390/diagnostics15141740}
}
EUVIMED